相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Optimization by moving ridge functions: derivative-free optimization for computationally intensive functions
James C. Gross et al.
ENGINEERING OPTIMIZATION (2022)
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
Anyue Yin et al.
CLINICAL PHARMACOKINETICS (2021)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C9andHLA-BGenotypes and Phenytoin Dosing: 2020 Update
Jason H. Karnes et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer
Alicja Puszkiel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions
Sebastian Frechen et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms
Eman El-Khateeb et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2021)
Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis
Jan-Georg Wojtyniak et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
Fatima Zahra Marok et al.
PHARMACEUTICS (2021)
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Matthew J. Page et al.
PLOS MEDICINE (2021)
Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization
Yahui Zhang et al.
FRONTIERS IN PHARMACOLOGY (2021)
An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine
Michelle Whirl-Carrillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement
Louise M. Andrews et al.
CLINICAL PHARMACOKINETICS (2020)
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
Kelly E. Caudle et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Knowledge and attitudes on pharmacogenetics among pediatricians
Shahad Rahawi et al.
JOURNAL OF HUMAN GENETICS (2020)
A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug-Drug-Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals
Nina Hanke et al.
CLINICAL PHARMACOKINETICS (2020)
Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer
Apostolos Papachristos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study
Aminah Almurjan et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2020)
Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes
Ru-jun Xu et al.
FRONTIERS IN PHARMACOLOGY (2020)
Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
Simeon Ruedesheim et al.
PHARMACEUTICS (2020)
Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
Ioannis Loisios-Konstantinidis et al.
PHARMACEUTICS (2020)
Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology
Xinyuan Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition
Evan D. Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics
Ute Schwarz et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
The role of pharmacogenomics in adverse drug reactions
Ramon Cacabelos et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
Denise Tuerk et al.
CLINICAL PHARMACOKINETICS (2019)
Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies
Yang Liu et al.
CLINICAL THERAPEUTICS (2019)
Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
Yoshinori Makino et al.
CANCER SCIENCE (2019)
A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients
L. M. Andrews et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Foreword
Luther T. Clark et al.
CURRENT PROBLEMS IN CARDIOLOGY (2019)
A Minimal Physiologically-Based Pharmacokinetic Model for Tacrolimus in Living-Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype
Kotaro Itohara et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium
Sook Wah Yee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy
Zaril Zakaria et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics
Andrea Gaedigk et al.
JOURNAL OF PERSONALIZED MEDICINE (2018)
Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis
Rui Li et al.
CLINICAL PHARMACOKINETICS (2018)
A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation
Louise M. Andrews et al.
CLINICAL PHARMACOKINETICS (2018)
Physiologically Based Pharmacokinetic Modeling in Regulatory Decision-Making at the European Medicines Agency
E. Luzon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Kelly E. Caudle et al.
GENETICS IN MEDICINE (2017)
Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine
Niloufar Marsousi et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
M. Verbelen et al.
PHARMACOGENOMICS JOURNAL (2017)
Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling
Jee Sun Min et al.
ARCHIVES OF PHARMACAL RESEARCH (2017)
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
A. S. Darwich et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy
Henrik Cordes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
Masahiro Hiratsuka
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2016)
US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014
Nadine Shehab et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
The Effect of Genetic Polymorphism on the Inhibition of Azole Antifungal Agents Against CYP2C9-Mediated Metabolism
Toshiro Niwa et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011
Dima M. Qato et al.
JAMA INTERNAL MEDICINE (2016)
Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis
Howard J. Burt et al.
DRUG METABOLISM AND DISPOSITION (2016)
Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity
Kayode Ogungbenro et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score
Linda M. Henricks et al.
PHARMACOGENOMICS (2015)
Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy
Kaitlyn Shaw et al.
THERAPEUTIC DRUG MONITORING (2015)
Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa
Ripudaman K. Bains et al.
BMC GENETICS (2013)
13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients
Geraldo Felicio Cunha-Junior et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma
T. M. Kerkhofs et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Derivative-free optimization: a review of algorithms and comparison of software implementations
Luis Miguel Rios et al.
JOURNAL OF GLOBAL OPTIMIZATION (2013)
Lessons Learned from Quantitative Dynamical Modeling in Systems Biology
Andreas Raue et al.
PLOS ONE (2013)
A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin
Mette M. H. Christensen et al.
PHARMACOGENETICS AND GENOMICS (2013)
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
A. Habtewold et al.
PHARMACOGENOMICS JOURNAL (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
CYP2B6 Pharmacogenetics-Based In Vitro-In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling
Cong Xu et al.
DRUG METABOLISM AND DISPOSITION (2013)
Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria
Joe Bentz et al.
DRUG METABOLISM AND DISPOSITION (2013)
Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes
Junling Yang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy
Celine Verstuyft et al.
CLINICAL PHARMACOKINETICS (2012)
Fundamentals of Population Pharmacokinetic Modelling
Catherine M. T. Sherwin et al.
CLINICAL PHARMACOKINETICS (2012)
Pharmacogenomics Knowledge for Personalized Medicine
M. Whirl-Carrillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Inter-individual Variability of In Vivo CYP2D6 Activity in Different Genotypes
Koji Chiba et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
In Vitro Assessment of the Allelic Variants of Cytochrome P450
Masahiro Hiratsuka
DRUG METABOLISM AND PHARMACOKINETICS (2012)
HLA and pharmacogenetics of drug hypersensitivity
Rebecca Pavlos et al.
PHARMACOGENOMICS (2012)
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development
D. R. Mould et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2012)
Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo
Cong Xu et al.
DRUG METABOLISM AND DISPOSITION (2012)
Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk
Sam Salman et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans
Motohiro Kato et al.
DRUG METABOLISM AND PHARMACOKINETICS (2010)
Estimation of the Interindividual Variability of Cytochrome 2D6 Activity from Urinary Metabolic Ratios in the Literature
Takashi Ito et al.
DRUG METABOLISM AND PHARMACOKINETICS (2010)
Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling
Thorsten Lehr et al.
PHARMACOGENETICS AND GENOMICS (2010)
Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study
S. Willmann et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Functional Characterization of the Human Organic Cation Transporter 2 Variant p.270Ala > Ser
Oliver Zolk et al.
DRUG METABOLISM AND DISPOSITION (2009)
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin
Ying Chen et al.
PHARMACOGENETICS AND GENOMICS (2009)
Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting
Tomohiro Sasaki et al.
PHARMACOGENOMICS (2009)
Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
I. S. Song et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
Zhi-Jun Wang et al.
PHARMACOGENETICS AND GENOMICS (2008)
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
Hongwu Shen et al.
DRUG METABOLISM AND DISPOSITION (2007)
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisularn exposure and higher risk of severe hematologic toxicity
Anthe S. Zandvliet et al.
CLINICAL CANCER RESEARCH (2007)
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy
A-K Hamberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
N Yasui-Furukori et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
M Ingelman-Sundberg
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Modeling the metabolic effects of terbutaline in β2-adrenergic receptor diplotypes
JJ Lima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
UM Zanger et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Inducibility of CYP1A2 by orneprazole in vivo related to the genetic polymorphism of CYP1A2
XM Han et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
分享论文
